Cellular Biomedicine (Nasdaq: CBMG) saw its shares rocket 16.6% to $23.55 in pre-market trading, after it revealed it had entered into a strategic licensing and collaboration agreement with Swiss pharma giant Novartis (NOVN: VX) to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.
In August last year, Novartis won the race to market the CAR T-cell-directed therapy, receiving US Food and Drug Administration approval for its Kymriah. In Europe, the drug received approval in August this year.
Novartis to make $40 million equity investment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze